Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $30.68 in the last session, down -1.41% from day before closing price of $31.12. In other words, the price has decreased by -$1.41 from its previous closing price. On the day, 1.06 million shares were traded. VRDN stock price reached its highest trading level at $31.535 during the session, while it also had its lowest trading level at $30.36.
Ratios:
We take a closer look at VRDN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 11.28 and its Current Ratio is at 11.28. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on December 10, 2025, Reiterated its Outperform rating but revised its target price to $47 from $42 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 31 ’25 when Tousignant Jennifer sold 2,272 shares for $31.16 per share. The transaction valued at 70,796 led to the insider holds 0 shares of the business.
Tousignant Jennifer bought 2,272 shares of VRDN for $70,796 on Dec 31 ’25. On Oct 23 ’25, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 454,545 shares for $22.00 each. As a result, the insider paid 9,999,990 and bolstered with 3,914,458 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 2928160768 and an Enterprise Value of 2650346752. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.36 while its Price-to-Book (P/B) ratio in mrq is 8.03. Its current Enterprise Value per Revenue stands at 37.44 whereas that against EBITDA is -8.176.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.94, which has changed by 0.5286497 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $34.04, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 5.35%, while the 200-Day Moving Average is calculated to be 56.74%.
Shares Statistics:
According to the various share statistics, VRDN traded on average about 1.58M shares per day over the past 3-months and 1457300 shares per day over the past 10 days. A total of 95.44M shares are outstanding, with a floating share count of 85.96M. Insiders hold about 9.93% of the company’s shares, while institutions hold 89.99% stake in the company. Shares short for VRDN as of 1765756800 were 9040297 with a Short Ratio of 5.74, compared to 1763078400 on 9472517. Therefore, it implies a Short% of Shares Outstanding of 9040297 and a Short% of Float of 9.83.
Earnings Estimates
A detailed examination of Viridian Therapeutics Inc (VRDN) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$1.08, with high estimates of -$0.92 and low estimates of -$1.26.
Analysts are recommending an EPS of between -$2.88 and -$4.72 for the fiscal current year, implying an average EPS of -$3.51. EPS for the following year is -$3.55, with 11.0 analysts recommending between -$2.33 and -$4.73.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for VRDN’s current fiscal year. The highest revenue estimate was $125.79M, while the lowest revenue estimate was $70.7M, resulting in an average revenue estimate of $87.69M. In the same quarter a year ago, actual revenue was $302kBased on 14 analysts’ estimates, the company’s revenue will be $87.15M in the next fiscal year. The high estimate is $215.97M and the low estimate is $15.09M.
